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BACKGROUND
Concern about the use of epinephrine as a treatment for out-of-hospital cardiac 
arrest led the International Liaison Committee on Resuscitation to call for a placebo-
controlled trial to determine whether the use of epinephrine is safe and effective in 
such patients.
METHODS
In a randomized, double-blind trial involving 8014 patients with out-of-hospital 
cardiac arrest in the United Kingdom, paramedics at five National Health Service 
ambulance services administered either parenteral epinephrine (4015 patients) or 
saline placebo (3999 patients), along with standard care. The primary outcome was 
the rate of survival at 30 days. Secondary outcomes included the rate of survival until 
hospital discharge with a favorable neurologic outcome, as indicated by a score of 
3 or less on the modified Rankin scale (which ranges from 0 [no symptoms] to 
6 [death]).
RESULTS
At 30 days, 130 patients (3.2%) in the epinephrine group and 94 (2.4%) in the pla-
cebo group were alive (unadjusted odds ratio for survival, 1.39; 95% confidence 
interval [CI], 1.06 to 1.82; P = 0.02). There was no evidence of a significant differ-
ence in the proportion of patients who survived until hospital discharge with a 
favorable neurologic outcome (87 of 4007 patients [2.2%] vs. 74 of 3994 patients 
[1.9%]; unadjusted odds ratio, 1.18; 95% CI, 0.86 to 1.61). At the time of hospital 
discharge, severe neurologic impairment (a score of 4 or 5 on the modified Rankin 
scale) had occurred in more of the survivors in the epinephrine group than in the 
placebo group (39 of 126 patients [31.0%] vs. 16 of 90 patients [17.8%]).
CONCLUSIONS
In adults with out-of-hospital cardiac arrest, the use of epinephrine resulted in a 
significantly higher rate of 30-day survival than the use of placebo, but there was 
no significant between-group difference in the rate of a favorable neurologic out-
come because more survivors had severe neurologic impairment in the epinephrine 
group. (Funded by the U.K. National Institute for Health Research and others; 
Current Controlled Trials number, ISRCTN73485024.)
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In attempting to reduce the rate of death and disability associated with cardiac arrest worldwide,1,2 emergency medical work-
ers have few effective treatments other than early 
initiation of cardiopulmonary resuscitation (CPR) 
and prompt defibrillation.3 For more than 50 years, 
treatment strategies have included the use of vari-
ous drugs, but there is limited evidence that such 
treatments are effective.4
Epinephrine (adrenaline) has potentially ben-
eficial effects in cardiac arrest through the con-
striction of arterioles mediated by α-adrenergic 
receptors. Such constriction increases aortic dia-
stolic pressure during CPR, thereby augmenting 
coronary blood flow and increasing the chance 
of a return of spontaneous circulation.5 Potentially 
harmful effects on the heart are mediated through 
β-adrenergic stimulation, which causes dysrhyth-
mias and increased myocardial oxygen demand 
and increases the risk of recurrent cardiac arrest.6 
In addition, α-adrenergic stimulation causes plate-
let activation, which promotes thrombosis7 and 
impairs the microvascular blood flow in the ce-
rebral cortex, which in turn increases the sever-
ity of cerebral ischemia during CPR and after a 
return of spontaneous circulation.8
Previous trials that have compared standard-
dose epinephrine (1 mg) with high-dose epineph-
rine (5 to 10 mg), with epinephrine and vaso-
pressin, or with placebo have not shown evidence 
of better outcomes.9 Observational studies involv-
ing more than 500,000 patients have reported 
higher rates of return of spontaneous circulation 
but worse neurologic outcomes in patients who 
were treated with epinephrine.10 The interpreta-
tion of these findings has been limited by con-
flicting results and the influence of unmeasured 
confounders. Thus, the International Liaison Com-
mittee on Resuscitation, a consortium of seven 
major organizations involved in the field of re-
suscitation worldwide, called for the initiation of 
a placebo-controlled trial to establish whether 
epinephrine is safe and effective as a treatment 
for cardiac arrest.4,11 Subsequently, we initiated the 
PARAMEDIC2 (Prehospital Assessment of the 
Role of Adrenaline: Measuring the Effectiveness 
of Drug Administration in Cardiac Arrest) trial 
to determine whether epinephrine is beneficial or 
harmful as a treatment for out-of-hospital cardiac 
arrest.12
Me thods
Trial Design and Oversight
From December 2014 through October 2017, the 
multicenter, randomized, double-blind, placebo-
controlled PARAMEDIC2 trial was conducted by 
five National Health Service ambulance services 
in the United Kingdom. The trial protocol (avail-
able with the full text of this article at NEJM.org) 
was developed by the investigators and has been 
published previously.12 The South Central–Oxford 
C Research Ethics Committee and the Medicines 
and Healthcare Products Regulatory Authority ap-
proved the protocol. The trial was designed and 
conducted in accordance with Directive 2001/20/EC 
of the European Parliament and Council, which 
was transposed into legislation in the United 
Kingdom by the Medicines for Human Use (Clin-
ical Trials) Regulations.
Because of the sudden and life-threatening na-
ture of cardiac arrest, and in accordance with Eu-
ropean legislation, the process of obtaining writ-
ten informed consent was deferred until after the 
emergency had passed. We sought written in-
formed consent to continue data collection after 
resuscitation from the patient or, if the patient 
lacked capacity, a legal representative. Additional 
details regarding the informed-consent process 
and patient and public involvement in the trial are 
provided in the Supplementary Appendix, avail-
able at NEJM.org.
The trial was funded by the Health Technology 
Assessment Programme of the National Institute 
for Health Research, with legal sponsorship pro-
vided by the University of Warwick. The funders 
had no role in the trial design, in the collection or 
analysis of the data, or in the writing of the manu-
script. The Warwick Clinical Trials Unit under-
took data management. The trial statisticians had 
full access to all the data and assume responsi-
bility for the integrity of the data, the complete-
ness and accuracy of the data and analysis, and 
the fidelity of the trial to the protocol.
Patient Population
Adult patients who had sustained an out-of-hospi-
tal cardiac arrest for which advanced life support 
was provided by trial-trained paramedics were eli-
gible for inclusion. Criteria for exclusion were 
known or apparent pregnancy, an age of less than 
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16 years, cardiac arrest from anaphylaxis or asth-
ma, or the administration of epinephrine before 
the arrival of the trial-trained paramedic. In one 
ambulance service, traumatic cardiac arrests were 
also excluded in accordance with local protocols.
Randomization and Treatment
Paramedic resuscitation protocols as outlined in 
the European Resuscitation Council Guidelines 
are described in the Supplementary Appendix.13 
If initial attempts at resuscitation (CPR and de-
fibrillation) were unsuccessful, the patient was 
randomly assigned to receive either parenteral 
epinephrine or saline placebo by the opening of 
a trial pack containing either agent. Uniquely num-
bered but otherwise identical-appearing trial packs 
contained 10 prefilled syringes, with each syringe 
containing either 1 mg of epinephrine or 0.9% 
saline. Single doses of epinephrine or saline were 
administered by an intravenous or intraosseous 
route every 3 to 5 minutes. The programming 
team at the Warwick Clinical Trials Unit provided 
randomization with concealed assignment. A ran-
domization sequence was computer-generated by 
the minimization method with an overall assign-
ment ratio of 1:1.
Ambulance services entered data into a secure 
electronic portal. Data definitions followed the 
Utstein recommendations.14 Data regarding the 
quality of the CPR results were obtained with 
the use of defibrillator downloads when avail-
able (Physiocontrol). Treatments were continued 
until a sustained pulse was achieved, resuscitation 
was discontinued, or care was handed over to cli-
nicians in the hospital. Hospital-based care was 
not specified in the trial protocol but was informed 
by national guidelines, which covered targeted 
temperature management, hemodynamic and ven-
tilatory criteria, and prognostication, as described 
in the Supplementary Appendix.15
Primary and Secondary Outcomes
The primary outcome was the rate of survival at 
30 days. The secondary outcomes were the rate of 
survival until hospital admission, the lengths of 
stay in the hospital and in the intensive care unit 
(ICU), the rates of survival at hospital discharge 
and at 3 months, and the neurologic outcomes at 
hospital discharge and at 3 months. We defined 
survival with a favorable neurologic outcome as 
a score of 3 or less on the modified Rankin scale 
(which ranges from 0 [no symptoms] to 6 [death]).16 
Outcomes were assessed by research paramedics, 
who were unaware of treatment assignments. We 
recorded serious adverse events (death, hospital-
ization, and disability) as trial outcomes. Other 
adverse events were reported directly to the trial 
office.
Statistical Analysis
We determined that the enrollment of 8000 pa-
tients would provide the best threshold to balance 
precision and practicality. With this target sam-
ple size, if the risk ratio for the epinephrine group 
was estimated to be 1.25, the corresponding 95% 
confidence interval would range from 1.07 to 1.46. 
A risk ratio of 1.25 corresponds to a rate of 30-day 
survival of 6.0% in the placebo group and 7.5% 
in the epinephrine group. Further information 
regarding the sample-size calculations is provided 
in the Supplementary Appendix.
The data and safety monitoring committee per-
formed interim reviews every 3 months. We used 
the Lan–DeMets, O’Brien–Fleming, and Pocock 
alpha spending methods to determine the upper 
and lower stopping boundaries for the primary 
outcome, with no adjustment in the final analysis.
The primary analysis was performed without 
adjustment in the modified intention-to-treat pop-
ulation, which included all the patients who had 
undergone randomization and were confirmed 
to have received the assigned intervention. Trial 
data were summarized by the calculation of means 
and standard deviations for normally distributed 
variables, medians and interquartile ranges for 
non-normally distributed variables, and frequency 
and percentage for categorical variables.
Survival outcomes were analyzed with the use 
of fixed-effect regression models with and with-
out adjustment for age, sex, the interval between 
the emergency call and the ambulance arrival at 
the scene, the interval between the ambulance ar-
rival and the administration of a trial agent, the 
cause of cardiac arrest, the initial cardiac rhythm, 
whether the cardiac arrest was witnessed, and 
whether CPR was performed by a bystander. The 
Hodges–Lehmann method was used to estimate 
median differences with 95% confidence inter-
vals for length-of-stay outcomes. In cases in which 
the proportional odds assumption was violated in 
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modeling of the score on the modified Rankin 
scale, partial proportional odds models were 
used. Scores on the modified Rankin scale were 
also analyzed as a binary outcome (with scores 
of 0 to 3 classified as “good” and scores of 4 to 
6 classified as “poor”). Unadjusted and adjusted 
odds ratios with 95% confidence intervals and 
mean differences with 95% confidence intervals 
were reported for categorical and continuous out-
comes, respectively. The number needed to treat 
and its 95% confidence interval were calculated 
for survival at 30 days. To aid in interpretation, 
we included a Bayesian analysis for the primary 
outcome and for survival with a favorable neuro-
logic outcome.
Prespecified subgroup analyses included the 
patient’s age, cause of cardiac arrest, initial car-
diac rhythm, whether the cardiac arrest was wit-
nessed, whether CPR was performed by a by-
stander, interval between the emergency call and 
ambulance arrival at the scene, interval between 
ambulance arrival and the trial-agent adminis-
tration, and the interval between the emergency 
call and trial-agent administration. A P value for 
interaction was reported in each analysis. Post hoc 
sensitivity analyses (which incorporated best-case 
and worst-case scenarios and multiple imputa-
tion) were conducted for survival at 30 days, sur-
vival at hospital discharge, and survival with a 
good neurologic outcome at discharge. All statis-
tical analyses were performed with the use of SAS 
software, version 9.4 (SAS Institute), and RStan.
R esult s
Patients and Interventions
Of 10,623 patients who were screened for eligi-
bility, 8103 (76.3%) were eligible, and trial packs 
were opened. The reasons for trial exclusion are 
shown in Figure 1. Between the opening of the 
trial packs and administration of epinephrine or 
placebo, further information indicated that 87 pa-
tients (1.1%) were ineligible to participate in the 
trial. Another 2 patients had unknown trial-group 
assignments because of missing trial-pack num-
bers. The remaining 8014 patients were assigned 
to the epinephrine group (4015 patients) or to the 
placebo group (3999 patients).
The characteristics of patients were well bal-
anced at baseline (Table 1), and concurrent treat-
ments were similar (Table S1 in the Supplemen-
tary Appendix). The key intervals in providing 
service (e.g., between the emergency call and 
ambulance arrival) were also similar in the two 
groups (Table 2). In the two groups, the median 
time from the emergency call to ambulance ar-
rival was 6.6 minutes (interquartile range, 4.2 to 
9.7), with a further 13.8 minutes (interquartile 
range, 9.5 to 19.0) elapsing until administration 
of the trial agent. The proportion of patients who 
had a return of spontaneous circulation during 
the prehospital resuscitation phase was higher in 
the epinephrine group than in the placebo group 
(36.3% vs. 11.7%), as was the proportion who 
were transported to the hospital (50.8% vs. 30.7%). 
The course of events for all the patients from initial 
enrollment to in-hospital death or hospital dis-
charge is shown in Figure S1 in the Supplementary 
Appendix.
Primary and Secondary Outcomes
Data for the primary outcome were available for 
4012 patients (99.9%) in the epinephrine group 
and 3995 patients (99.9%) in the placebo group. 
In the epinephrine group, 130 patients (3.2%) were 
alive at 30 days, as compared with 94 patients 
(2.4%) in the placebo group (unadjusted odds ratio 
for survival, 1.39; 95% confidence interval [CI], 
1.06 to 1.82; P = 0.02) (Table 3). The number of 
patients who would need to be treated with epi-
nephrine to prevent one death at 30 days was 112 
(95% CI, 63 to 500). The Kaplan–Meier curves for 
survival at day 30 are shown in Figure S2 in the 
Supplementary Appendix.
There was no evidence of a significant differ-
ence between the epinephrine group and the pla-
cebo group in the proportion of patients who 
survived until hospital discharge with a favorable 
neurologic outcome (87 of 4007 patients [2.2%] 
and 74 of 3994 patients [1.9%], respectively; un-
adjusted odds ratio, 1.18; 95% CI, 0.86 to 1.61) 
(Table 3, and Table S2 in the Supplementary Ap-
pendix). Severe neurologic impairment (a score 
of 4 or 5 on the modified Rankin scale) was more 
common among survivors in the epinephrine 
group than in the placebo group (39 of 126 pa-
tients [31.0%] vs. 16 of 90 patients [17.8%]) 
(Fig. 2). The results with respect to survival at 
3 months and neurologic outcomes at 3 months 
were similar in the two groups (Table 3, and 
Table S3 in the Supplementary Appendix).
In a Bayesian analysis that used an assump-
tion of no benefit from adrenaline, the posterior 
probability that the absolute rate of survival was 
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at least 1 percentage point higher in the epineph-
rine group than in the placebo group was 37% 
(Fig. S3 in the Supplementary Appendix). The prob-
ability that the absolute survival rate was at least 
2 percentage points higher was 0.2%. With respect 
to the rate of survival with a favorable neurologic 
Figure 1. Enrollment and Outcomes.
Among the patients who were lost to follow-up before the primary outcome analysis, 6 (3 in the epinephrine group 
and 3 in the placebo group) declined to provide consent for the continuation of data collection after resuscitation. 
Hospital discharge may have occurred at any point from randomization to a time after the 3-month follow-up period.
8103 Underwent randomization
(pack opened)
10,623 Patients were assessed for eligibility
2520 Were excluded
268 Were known or suspected to be <16 yr
of age
17 Were known or suspected to be pregnant
615 Had return of spontaneous circulation
17 Had cardiac arrest secondary to anaphylaxis
183 Had cardiac arrest secondary to life-
threatening asthma
1192 Received adrenaline before ambulance arrival
228 Had traumatic arrest excluded by London
Ambulance Service
87 Were excluded after randomization
4 Had do-not-resuscitate order
6 Had asthma
22 Had return of spontaneous circulation
2 Were pregnant
4 Had broken or contaminated syringes
2 Had no intravenous access
47 Had unknown reason
2 Had missing study-group assignment
owing to lost pack number
3999 Received placebo 4015 Received epinephrine
3995 Were included in the primary analysis 4012 Were included in the primary analysis
8 Were lost to follow-up in survival analysis
4 Were lost before 30-day analysis
4 Were lost before 3-mo analysis
20 Were lost to follow-up in neurologic analysis
5 Were lost before hospital-discharge analysis
15 Were lost before 3-mo analysis
6 Were lost to follow-up in survival analysis
3 Were lost before 30-day analysis
3 Were lost before 3-mo analysis
29 Were lost to follow-up in neurologic analysis
8 Were lost before hospital-discharge analysis
21 Were lost before 3-mo analysis
8016 Were enrolled in the trial
(pack opened, drug given)
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outcome at hospital discharge, the probabilities 
that the rate was at least 1 or 2 percentage points 
higher with epinephrine were 1.9% and 0%, re-
spectively (Fig. S4 in the Supplementary Appendix).
The other secondary outcomes are presented 
in Table 3. Among the patients who were admit-
ted to the hospital, there were no significant be-
tween-group differences in the length of stay in 
the hospital or ICU (Figs. S5 and S6 in the Sup-
plementary Appendix). There was no statistical 
evidence of a modification in treatment effect by 
such factors as the patient’s age, whether the 
cardiac arrest was witnessed, whether CPR was 
performed by a bystander, initial cardiac rhythm, 
or response time or time to trial-agent adminis-
tration (Fig. S7 in the Supplementary Appendix). 
Characteristic
Epinephrine 
(N = 4015)
Placebo 
(N = 3999)
Mean age ±SD — yr 69.7±16.6 69.8±16.4
Sex — no. (%)
Male 2609 (65.0) 2584 (64.6)
Female 1406 (35.0) 1415 (35.4)
Initial cardiac rhythm — no. (%)
Shockable 770 (19.2) 748 (18.7)
Ventricular fibrillation 716 (17.8) 684 (17.1)
Pulseless ventricular tachycardia 25 (0.6) 20 (0.5)
Not otherwise identified with AED 29 (0.7) 44 (1.1)
Nonshockable 3149 (78.4) 3181 (79.5)
Asystole 2135 (53.2) 2194 (54.9)
Pulseless electrical activity 955 (23.8) 937 (23.4)
Bradycardia 20 (0.5) 16 (0.4)
Not otherwise identified with AED 39 (1.0) 34 (0.9)
Undetermined
Not identified 4 (0.1) 1 (<0.1)
Missing data 92 (2.3) 69 (1.7)
Cause of cardiac arrest — no. (%)
Medical cause 3656 (91.1) 3691 (92.3)
Traumatic cause 66 (1.6) 57 (1.4)
Drowning 10 (0.2) 10 (0.3)
Drug overdose 74 (1.8) 72 (1.8)
Electrocution 0 1 (<0.1)
Asphyxia 117 (2.9) 81 (2.0)
Not identified 1 (<0.1) 2 (0.1)
Missing data 91 (2.3) 85 (2.1)
Witness of cardiac arrest — no. (%)
None 1498 (37.3) 1505 (37.6)
Paramedic 452 (11.3) 470 (11.8)
Bystander 2013 (50.1) 1967 (49.2)
Not identified 1 (<0.1) 1 (<0.1)
Missing data 51 (1.3) 56 (1.4)
CPR performed — no. (%)
By bystander 2382 (59.3) 2349 (58.7)
By paramedic during witnessed event 452 (11.3) 470 (11.8)
Not identified 1 (<0.1) 1 (<0.1)
Missing data 69 (1.7) 84 (2.1)
*  There were no significant between-group differences in any of the baseline characteristics. AED denotes automated ex-
ternal defibrillator, and CPR cardiopulmonary resuscitation.
Table 1. Characteristics of the Patients at Baseline.*
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Sensitivity analyses that incorporated the best-case 
and worst-case scenarios and multiple imputation 
confirmed the findings of the main trial results 
(Table S3 in the Supplementary Appendix). No ad-
ditional serious adverse events were reported.
Discussion
In this trial, the use of epinephrine during resus-
citation for out-of-hospital cardiac arrest resulted 
in a significantly higher rate of survival at 30 days 
than the use of placebo. Patients in the epineph-
rine group had a higher rate of return of sponta-
neous circulation, a higher frequency of transport 
to the hospital, and a higher rate of treatment in 
the ICU. However, although the rate of survival 
was slightly better, the trial did not show evidence 
of a between-group difference in the rate of sur-
vival with a favorable neurologic outcome. This 
result was explained by a higher proportion of 
patients who survived with severe neurologic dis-
ability in the epinephrine group.
A meta-analysis of six randomized trials in-
volving 6174 patients in which investigators com-
pared standard-dose epinephrine (1 mg) with 
high-dose epinephrine (5 to 10 mg) showed better 
Variable
Epinephrine 
(N = 4015)
Placebo 
(N = 3999)
Interval between emergency call and ambulance arrival at scene
No. of patients in analysis 4015 3999
Median (IQR) — min† 6.7 (4.3–9.7) 6.6 (4.2–9.6)
Interval between emergency call and administration of trial agent
No. of patients in analysis 3975 3949
Median (IQR) — min† 21.5 (16.0–27.3) 21.1 (16.1–27.4)
Interval between ambulance arrival at scene and departure
No. of patients in analysis 2039 1226
Mean — min 50.1±21.8 44.5±18.3
Interval between ambulance departure from scene and hospital  
arrival
No. of patients in analysis 2038 1225
Mean — min 12.9±9.8 12.4±8.9
Median interval between initiation of advanced life support and  
cessation (IQR) — min
47.5 (35.1–64.0) 43.1 (33.5–56.1)
Return of spontaneous circulation — no. (%)
Yes 1457 (36.3) 468 (11.7)
No 2518 (62.7) 3492 (87.3)
Missing data 40 (1.0) 39 (1.0)
Transportation of patient to hospital — no. (%)
Yes 2041 (50.8) 1227 (30.7)
No 1974 (49.2) 2772 (69.3)
Declaration of death by emergency department staff — no. (%)
Yes 988 (24.6) 689 (17.2)
No 614 (15.3) 290 (7.3)
Not applicable because not transported 1974 (49.2) 2772 (69.3)
Missing data 439 (10.9) 248 (6.2)
*  Plus–minus values are means ±SD. IQR denotes interquartile range.
†  Among cardiac arrests that were witnessed by paramedics, the interval between the emergency call and the cardiac 
event was considered to be 0 minutes.
Table 2. Intervals between Key Events and Initial Response to Resuscitation.*
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rates of return of spontaneous circulation and 
hospital admission with the high-dose regimen but 
no significant between-group difference in the 
rates of survival until hospital discharge or sur-
vival with a favorable neurologic outcome.9 These 
data, combined with evidence of greater myocar-
dial dysfunction after a return of spontaneous 
circulation with high-dose epinephrine, led to 
international recommendations against the use 
of high-dose epinephrine in 2000.17 In the Pre-
hospital Adrenaline for Cardiac Arrest (PACA) 
trial comparing standard-dose epinephrine with 
placebo,18 the result was inconclusive, since only 
10% of the intended patients were recruited and 
information regarding treatment assignment was 
unavailable for 10% of the patients who under-
went randomization.
The benefit of epinephrine for survival that 
we found in our trial should be considered in 
comparison with other treatments in the chain 
of survival.19 The number of patients who would 
need to be treated with epinephrine to prevent 
one death after cardiac arrest was 112, as com-
pared with early recognition of cardiac arrest 
(number needed to treat, 11),20 CPR performed by 
a bystander (number needed to treat, 15),21 and 
early defibrillation (number needed to treat, 5).22
The reasons that the use of epinephrine did 
not improve neurologic outcome in this trial are 
uncertain. One explanation is that although epi-
nephrine increases macroscopic cerebral blood 
flow, it paradoxically impairs cerebral microvas-
cular blood flow and thus has the potential to 
worsen brain injury after a return of spontaneous 
Outcome Epinephrine Placebo
Odds Ratio 
(95% CI)†
Unadjusted Adjusted
Primary outcome
Survival at 30 days — no./total no. (%)‡ 130/4012 (3.2) 94/3995 (2.4) 1.39 
(1.06–1.82)
1.47 
(1.09–1.97)
Secondary outcomes
Survival until hospital admission —  
no./total no. (%)§
947/3973 (23.8) 319/3982 (8.0) 3.59 
(3.14–4.12)
3.83 
(3.30–4.43)
Median length of stay in ICU (IQR) — days
Patients who survived 7.5 (3.0–15.0) 7.0 (3.5–12.5) NA NA
Patients who died¶ 2.0 (1.0–5.0) 3.0 (1.0–5.0) NA NA
Median length of hospital stay (IQR)
Patients who survived 21.0 (10.0–41.0) 20.0 (9.0–38.0) NA NA
Patients who died‖ 0 0 NA NA
Survival until hospital discharge —  
no./total no. (%)
128/4009 (3.2) 91/3995 (2.3) 1.41 
(1.08–1.86)
1.48 
(1.10–2.00)
Favorable neurologic outcome at hospital 
discharge — no./total no. (%)
87/4007 (2.2) 74/3994 (1.9) 1.18 
(0.86–1.61)
1.19 
(0.85–1.68)
Survival at 3 mo — no./total no. (%) 121/4009 (3.0) 86/3991 (2.2) 1.41 
(1.07–1.87)
1.47 
(1.08–2.00)
Favorable neurologic outcome at 3 mo — 
no./total no. (%)
82/3986 (2.1) 63/3979 (1.6) 1.31 
(0.94–1.82)
1.39 
(0.97–2.01)
*  ICU denotes intensive care unit, and NA not applicable.
†  The odds ratio is for the epinephrine group as compared with the placebo group. Odds ratios were adjusted for patients’ age, sex, interval 
between emergency call and ambulance arrival at scene, interval between ambulance arrival at scene and administration of the trial agent, 
initial cardiac rhythm, cause of cardiac arrest, whether the cardiac arrest was witnessed, and whether CPR was performed by a bystander.
‡  P = 0.02 for the between-group comparison in the primary analysis.
§  Survival until hospital admission was defined as a sustained return of spontaneous circulation until admission and transfer of care to medi-
cal staff at the receiving hospital (also defined as “survived event”).
¶  Among the patients who died, the length of stay in the ICU is for all the patients who were admitted to and died in the ICU.
‖  Among the patients who died, the length of stay in the hospital is for all the patients who died before hospital discharge.
Table 3. Primary and Secondary Outcomes.*
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circulation.8,23 An alternative explanation is that 
the brain is more sensitive to ischemia and reper-
fusion injury and less able to functionally recover 
after restoration of circulation than are the heart 
and other organs.24,25 No specific therapies other 
than targeted temperature management have been 
shown to reduce the severity of brain injury after 
cardiac arrest.15
Clinical decision making must balance the 
burdens and benefits of treatment. The burdens 
of treatment are high in cardiac arrest, since 
resuscitation is an invasive procedure with sub-
stantial risks of complications.26 If resuscitation 
is initially successful, most patients require con-
tinuation of life-sustaining therapies in the ICU 
for several days.27 Treatment is withdrawn in one 
third of patients, and a further third of patients 
die,27 predominantly from the consequences of 
severe brain injury.28 In such patients, the bene-
fits of epinephrine that were identified in our 
trial are small, since they would result in 1 extra 
survivor for every 112 patients treated. This num-
ber is less than the minimal clinically important 
difference that has been defined in previous stud-
ies.29,30 Among the survivors, almost twice the 
number in the epinephrine group as in the pla-
cebo group had severe neurologic impairment.
Our work with patients and the public before 
starting the trial (as summarized in the Supple-
mentary Appendix) identified survival with a fa-
vorable neurologic outcome to be a higher prior-
ity than survival alone. The Core Outcome Set for 
Cardiac Arrest (COSCA) was developed by pa-
tients and clinicians16; neurologic outcome and 
health-related quality of life were prioritized along 
with survival as the most important outcomes. 
Patients may be less willing to accept burdensome 
treatments if the chances of recovery are small 
or the risk of survival with an impaired neuro-
logic outcome is high.31,32
Our trial has several limitations. According to 
the protocol, paramedics administered intermit-
tent 1-mg boluses of epinephrine, whereas other 
strategies (e.g., different doses or dosing intervals) 
might have produced different results. Earlier ad-
ministration of epinephrine could also have influ-
enced the results, although data concerning the 
benefit of early drug administration are conflict-
ing.33-35 We did not collect information regarding 
the patients’ baseline neurologic status, although 
the number of patients who had impaired neuro-
logic function before cardiac arrest is likely to 
have been very small and balanced between the 
two groups. The original protocol anticipated a 
higher survival rate than the one that was ob-
served. This result probably reflects the overall 
poor prognosis among patients who do not have 
a response to initial CPR and defibrillation and 
is similar to findings in other studies.7,36 Infor-
mation about the quality of CPR was limited to 
the first 5 minutes of cardiac arrest and involved 
fewer than 5% of the enrolled patients. Although 
national guidelines inform the care that patients 
receive after resuscitation, we did not mandate or 
monitor for adherence with specific protocols.
In conclusion, in this randomized trial involv-
ing patients with out-of-hospital cardiac arrest, 
the use of epinephrine resulted in a significantly 
higher rate of survival at 30 days than the use of 
placebo, but there was no significant between-
group difference in the rate of a favorable neuro-
logic outcome because more survivors had severe 
neurologic impairment in the epinephrine group.
Supported by the Health Technology Assessment Programme 
of the National Institute for Health Research in the United King-
dom; by the Comprehensive Research Network Intensive Care 
Foundation and Out of Hospital Cardiac Arrest Registry, which 
is funded by the British Heart Foundation and Resuscitation 
Council; and by Health Care Wales.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
Figure 2. Survival with a Favorable Neurologic Outcome at Hospital  
Discharge.
Shown is the distribution of patients’ scores on the modified Rankin scale, 
which ranges from 0 (no symptoms) to 6 (death). Survival until hospital 
discharge with a favorable neurologic outcome, as indicated by a score  
of 3 or less on the modified Rankin scale, occurred in 87 of 4007 patients 
(2.2%) in the epinephrine group and in 74 of 3994 patients (1.9%) in the 
placebo group. However, severe neurologic impairment (a score of 4 or 5) 
was more frequent in the epinephrine group than in the placebo group  
(39 of 126 patients [31.0%] vs. 16 of 90 patients [17.8%]). The patients who 
died before hospital discharge are indicated by a score of 6 on the scale. 
The data are presented on a log10 scale of the percentages of patients in 
each group.
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